Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597388 · ClinicalTrials.gov registry record · Phase 1
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT01597388 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 99 participants.
The verdict
NCT01597388, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Interventions
- DRUG Fulvestrant
- DRUG AZD2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-05-08 |
| Est. Completion | 2026-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01597388
The ClinicalTrials.gov registry entry for NCT01597388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT01597388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01597388 about?
NCT01597388 is a clinical study titled "AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer". The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
What is the current status of trial NCT01597388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2012-05-08. Estimated completion is 2026-01-13.
What interventions are being tested in trial NCT01597388?
The interventions under investigation include: Fulvestrant (DRUG), AZD2014 (DRUG).
Who is sponsoring clinical trial NCT01597388?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.